Last reviewed · How we verify
Pegylated rhEPO
Pegylated rhEPO is a Small molecule drug developed by Xiamen Amoytop Biotech Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Pegylated rhEPO |
|---|---|
| Sponsor | Xiamen Amoytop Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated rhEPO CI brief — competitive landscape report
- Pegylated rhEPO updates RSS · CI watch RSS
- Xiamen Amoytop Biotech Co., Ltd. portfolio CI
Frequently asked questions about Pegylated rhEPO
What is Pegylated rhEPO?
Pegylated rhEPO is a Small molecule drug developed by Xiamen Amoytop Biotech Co., Ltd..
Who makes Pegylated rhEPO?
Pegylated rhEPO is developed by Xiamen Amoytop Biotech Co., Ltd. (see full Xiamen Amoytop Biotech Co., Ltd. pipeline at /company/xiamen-amoytop-biotech-co-ltd).
What development phase is Pegylated rhEPO in?
Pegylated rhEPO is in Phase 1.
Related
- Manufacturer: Xiamen Amoytop Biotech Co., Ltd. — full pipeline